高级检索
当前位置: 首页 > 详情页

Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Dept Resp Med, Shijiazhuang, Peoples R China [2]Hebei Med Univ, Dept Oncol, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebel, Peoples R China
出处:
ISSN:

关键词: Chemoresistance Lung cancer Periostin Stat3 signaling Therapeutic target

摘要:
Background/Aims: Periostin is upregulated in non-small cell lung cancer (NSCLC). This study was done to explore the function of periostin in the development of cisplatin (CDDP) resistance in NSCLC. Methods: The effects of overexpression or knockdown of periostin on CDDP sensitivity was examined in A549 cells. The involvement of signal transducer and activator of transcription 3 (Stat3) and Akt signaling in the action of periostin was checked. The in vivo effect of periostin silencing on CDDP susceptibility was determined in a mouse xenograft model. Results: Periostin was significantly upregulated in CDDP-resistant A549 cells, compared to parental controls. Overexpression of periostin rendered A549 cells more resistant to CDDP-induced apoptosis and enhanced Stat3 and Akt phosphorylation and survivin expression. Periostin-mediated protection against CDDP-induced apoptosis was compromised by downregulation of survivin. Furthermore, knockdown of periostin re-sensitized CDDP-resistant A549 cells to CDDP. After CDDP treatment, greater volume reduction was observed in periostin-silenced xenograft tumors than in control tumors, which was accompanied by reduced levels of phosphorylated Stat3 and survivin in periostin-depleted tumors. Conclusion: In conclusion, periostin promotes CDDP resistance in NSCLC cells largely through activation of Stat3 and Akt and upregulation of survivin and thus represents a promising target for overcoming CDDP resistance. (C) 2016 The Author(s) Published by S. Karger AG, Basel

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 2 区 生物
小类 | 2 区 生理学 3 区 细胞生物学
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 细胞生物学 4 区 生理学
JCR分区:
出版当年[2016]版:
Q1 PHYSIOLOGY Q2 CELL BIOLOGY
最新[2023]版:
Q2 PHYSIOLOGY Q3 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Resp Med, Shijiazhuang, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Dept Oncol, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebel, Peoples R China [*1]Department of Oncology, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, Hebei 050017 (China)
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号